Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Randomized, Double-Blind, Placebo-Controlled Study of LAM-002A for the Prevention of Progression of COVID-19

NCT04446377 is registered in ClinicalTrials.gov with OrphAI Therapeutics as lead sponsor.

NCT NCT04446377
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04446377 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Randomized, Double-Blind, Placebo-Controlled Study of LAM-002A for the Prevention of Progression of COVID-19
Lead sponsor
OrphAI Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
July 15, 2020
Completion date
April 19, 2021
Enrollment
142 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19 disease